کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1393119 | 1501182 | 2010 | 6 صفحه PDF | دانلود رایگان |

A series of rhodanine compounds containing various substituents at the N3- and C5-positions were synthesized and their in vitro activity against a panel of clinically relevant MRSA strains was determined. The anti-MRSA activity of compounds 21 (MIC = 3.9 μg/mL, MBC = 7.8 μg/mL) and 22 (MIC = 1.95 μg/mL, MBC = 7.8 μg/mL) was significantly greater than that of the lead compounds, 1–3 and reference antibiotics penicillin G (MIC = 31.25 μg/mL) and ciprofloxacin (MIC = 7.8 μg/mL) and comparable to that of vancomycin (MIC = 0.97 μg/mL). Compounds 21 and 22 were found to be bactericidal at only 2–4-fold higher than their MIC concentrations. In addition, their MIC values remained unchanged in the presence or absence of 10% serum. Overall, the results suggest that compounds 21 and 22 may be of potential use in the treatment of MRSA infections.
The anti-MRSA activity of the phenylalanine-derived rhodanine analogs 21 (MIC = 3.9 μg/mL, MBC = 7.8 μg/mL) and 22 (MIC = 1.95 μg/mL, MBC = 7.8 μg/mL) was found to be comparable to the reference antibiotic vancomycin (MIC = 0.97 μg/mL).Figure optionsDownload as PowerPoint slide
Journal: European Journal of Medicinal Chemistry - Volume 45, Issue 12, December 2010, Pages 5827–5832